Cervical Human Papillomavirus Testing: Current and Future Impact on Patient Care

Area of Science:

• Oncology
• Virology
• Molecular Diagnostics

Background:

• Cervical cancer is a significant global health concern, ranking as the fourth most common malignancy in women.
• Human papillomavirus (HPV) is the primary etiological agent responsible for the vast majority of cervical cancer cases.

Purpose of the Study:

• To review and compare six Food and Drug Administration (FDA)-approved HPV molecular diagnostic platforms.
• To discuss the role of HPV vaccination in cervical cancer prevention.
• To explore the emerging strategy of HPV self-collection for screening.

Main Methods:

• Literature review of FDA-approved HPV molecular diagnostic platforms.
• Analysis of advantages and disadvantages of each platform.
• Discussion of HPV vaccination and self-collection strategies.

Main Results:

• Six distinct HPV molecular platforms have received FDA approval, each offering unique performance characteristics.
• HPV vaccination has proven effective in reducing HPV infection rates.
• HPV self-collection presents a viable alternative for cervical cancer screening.

Conclusions:

• HPV molecular diagnostics are essential tools for cervical cancer screening and prevention.
• A comprehensive approach including vaccination, molecular testing, and potentially self-collection can enhance cervical cancer control efforts.